Disease State Plasma
Specialists in Disease State Plasma
BBI specialises in sourcing very specific Disease State Plasma products to support applications in autoimmunity, infectious disease testing and interference testing. Materials are sourced from highly reputable partners in Europe and in the USA that collect the plasma on behalf of BBI to a defined specification. Our partners have been assessed by BBI for the quality of the material they can provide but also for the information provided with the disease state plasma.
BBI rarely relies on approval of pre-shipment samples, relying instead on the provision of material to a defined titre specification using standardised testing methodologies. Materials are collected to order, and these bespoke collections may take longer but the quality and titre of the material is guaranteed. BBI specialises in the supply of Anti-TPO and Anti-Tg positive plasmas along with Pregnancy serum and some specific infectious disease such as Hepatitis B surface antigen. BBI also has a unique, popular “synthetic” disease state plasma for Rubella IgM that has been characterised for dose response linearity on several commercial immunoassay platforms.
The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.
Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.
Novarum™ technology transforms a smartphone into a diagnostic test reader, empowering users to read and share the results of rapid tests from the point of care. Our pioneering technology can be used by anyone, anywhere, with minimal training: connecting patients and doctors, field workers, lab researchers and primary care clinicians to specialist practices as part of a mobile eco-system.